Diabetes Drugs Market and Trend

Diabetes drugs are used to lower the concentration of glucose in the blood to treat diabetes. Except for insulin, exenatide, liraglutide and pramlintide are taken by mouth, so they are called oral hypoglycemic drugs. There are two type diabetes:

Type 1 diabetes is caused by a lack of insulin, so it needs to be treated with insulin injections.

Type 2 diabetes occurs because cells become resistant to insulin and can be treated with:

A. cause the pancreas to increase insulin secretion.

B. increases the sensitivity of cells to insulin.

C. Decreases the rate of glucose absorption from the gastrointestinal tract.

The global diabetes drugs market size was USD 37.6 billion in 2017, growing to USD 54.2 billion in 2022, with a CAGR of 7.6% from 2017 to 2022. The global diabetes drugs market size is expected to reach USD 71.7 billion in 2027, with a CAGR of 5.8% from 2022 to 2027.

Figure 2017-2027 Global Diabetes Drugs Market Size (Billion USD) and CAGR

The top 10 drugs in the global diabetes drugs market are glargine insulin, liraglutide, sitagliptin phosphate, dulaglutide, lysergic acid insulin, menthol insulin, enkephalin, metformin, liragliptin, and detergent insulin.